A case of reversible posterior leucoencephalopathy syndrome after rituximab infusion

Target Practice: Lessons from Phase III Trials with Bevacizumab and Vatalanib in the Treatment of Advanced Colorectal Cancer

“…A very rare side effect of bevacizumab is reversible posterior encephalopathy syndrome (RPLS) [39,40]. RPLS is a braincapillary leak syndrome related to hypertension, fluid retention, and the cytotoxic effects of immunosuppressive agents on vascular endothelium [41][42][43]. Clinicians should be aware of this potential complication.…”

Oligosymptomatic Reversible Posterior Leukoencephalopathy in a Patient With Lupus Nephritis

“…The neuroradiographic exams are really useful in patients with an atypical onset like our patient, who had significantly slight signs and symptoms according to the typical RPL [6][7][8][9]. Physicians should be aware of this variability because it may hinder a correct diagnosis and treatment.…”

Posterior Reversible Leukoencephalopathy Syndrome in a patient after second dose of Rituximab for treatment of resistant Thrombotic Thrombocytopenic Purpura

“…There are no pathognomonic clinical features of PRES but it can present with various neurological symptoms that include altered level of consciousness (ranging from confusion to coma), seizure activity, focal neurological signs, visual abnormalities, headache, nausea and vomiting [2,5,6]. The diagnosis is con irmed by radiological indings of bilateral and symmetric regions of oedema in the white matter, predominantly involving the posterior and occipital lobes, though occasionally it is seen involving the frontal lobe, temporal lobe, basal ganglia, cerebellum and brainstem; and cortex, instead of the white matter.…”

“…Recently, many cases have been reported to have occurred after administration of Rituximab (anti-CD20 monoclonal antibody), used for treatment of various lymphoproliferative disorders, refractory TTP, rheumatologic disorders and glomerulonephritides [3,[6][7][8][9]. Various case reports show that PRES can occur within hours to days after administration of rituximab [3] and there is no speci ic relationship of the number of doses given with the onset of PRES, which has also been observed after administration of fourth dose of rituximab [7].…”